Victory Capital Management Inc. Has $23.83 Million Stock Position in Vaxcyte, Inc. (NASDAQ:PCVX)

Victory Capital Management Inc. reduced its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 12.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 379,407 shares of the company’s stock after selling 51,542 shares during the quarter. Victory Capital Management Inc. owned 0.40% of Vaxcyte worth $23,827,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the stock. Bank of New York Mellon Corp raised its position in shares of Vaxcyte by 3.8% during the third quarter. Bank of New York Mellon Corp now owns 396,031 shares of the company’s stock valued at $20,190,000 after buying an additional 14,375 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Vaxcyte by 12.7% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,924 shares of the company’s stock worth $557,000 after acquiring an additional 1,233 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Vaxcyte by 4.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 50,840 shares of the company’s stock worth $2,592,000 after purchasing an additional 2,217 shares in the last quarter. Chicago Partners Investment Group LLC increased its position in shares of Vaxcyte by 16.3% during the third quarter. Chicago Partners Investment Group LLC now owns 7,162 shares of the company’s stock valued at $336,000 after purchasing an additional 1,005 shares during the period. Finally, TD Asset Management Inc raised its stake in shares of Vaxcyte by 69.7% in the third quarter. TD Asset Management Inc now owns 151,146 shares of the company’s stock valued at $7,705,000 after purchasing an additional 62,101 shares in the last quarter. 96.78% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have weighed in on PCVX. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vaxcyte in a research note on Friday, January 12th. Needham & Company LLC reiterated a “buy” rating and set a $95.00 target price on shares of Vaxcyte in a research report on Wednesday, April 10th. Four analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $78.50.

Insider Activity

In related news, SVP Elvia Cowan sold 11,678 shares of the firm’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $74.08, for a total transaction of $865,106.24. Following the completion of the sale, the senior vice president now directly owns 12,480 shares of the company’s stock, valued at approximately $924,518.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, SVP Elvia Cowan sold 11,678 shares of the stock in a transaction on Friday, March 1st. The stock was sold at an average price of $74.08, for a total transaction of $865,106.24. Following the sale, the senior vice president now owns 12,480 shares in the company, valued at $924,518.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Jim Wassil sold 3,000 shares of Vaxcyte stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $73.71, for a total value of $221,130.00. Following the completion of the transaction, the chief operating officer now directly owns 220,852 shares of the company’s stock, valued at $16,279,000.92. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 63,294 shares of company stock worth $4,254,105. Insiders own 3.10% of the company’s stock.

Vaxcyte Price Performance

Shares of NASDAQ:PCVX opened at $66.79 on Thursday. The stock has a market capitalization of $7.24 billion, a price-to-earnings ratio of -16.17 and a beta of 0.94. The business’s fifty day moving average price is $66.30 and its two-hundred day moving average price is $62.42. Vaxcyte, Inc. has a fifty-two week low of $44.20 and a fifty-two week high of $82.04.

Vaxcyte (NASDAQ:PCVX) last announced its earnings results on Tuesday, February 27th. The company reported ($1.82) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.93). During the same period last year, the business posted ($0.73) EPS. Research analysts expect that Vaxcyte, Inc. will post -4.18 EPS for the current fiscal year.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.